Triastek, Inc.
Monday, June 03, 2024
Other
Company Presentation Theater 4
We have created the Melt Extrusion Deposition (MED®) 3D printing pharmaceutical process, transforming the delivery, development, and production of medication through digital product development and continuous manufacturing. We design and develop transformative medications for patients. Through collaboration with global pharmaceutical companies, we tackle challenging formulation issues, accelerating the development of new drug products and improving the quality of pharmaceuticals.
Company Website:
http://www.triastek.com
Lead Product in Development:
T19, T20, T21
Company HQ City
Nanjing
Company HQ State
Jiangsu Province
Company HQ Country
China
CEO/Top Company Official
Dr. Senping Cheng
Development Phase of Primary Product
Pre-Clinical
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())